NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business...
87 Views
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business...
105 Views
NRBO: Positive SAD Part 1 Data MAD Part 2 Results Expected in 1Q25
On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced positive topline results from the single ascending dose (SAD) Part 1 portion...
221 Views
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24
On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the second quarter of 2024 and provided a business...
161 Views
NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024
On May 22, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced that preclinical data of DA-1241 in combination with semaglutide in mouse models...
213 Views
No more insights